Pre-made Nurulimab benchmark antibody ( Whole mAb, anti-CTLA4/CTLA-4 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nurulimab (also known as BCD 145) is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) for the treatment of cancer

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-382-1mg	1mg	3090
GMP-Bios-ab-382-10mg	10mg	Inquiry
GMP-Bios-ab-382-100mg	100mg	Inquiry
GMP-Bios-ab-382-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nurulimab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name	Nurulimab
Target	CTLA-4
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	5xj3:AB/5tru:HL/6jc2:HL
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Biocad
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Malignant melanoma
Development Tech	na